Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials is a research paper published in Molecular Therapy (2022). On theSindex it has a DataRank of 0.475. It has been cited 11 times, with 7 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.373
From this paper's citation signal
Citation Network Contribution
0.102
From 5 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 7 citers.
U.S. Department of Defense
Grant: CA180889
U.S. Department of Defense
Grant: CA200437
American Association for Cancer Research
Grant: 604817
Leukemia and Lymphoma Society
Grant: P3CA008748
National Heart, Lung, and Blood Institute
Grant: P40HL116212
National Heart, Lung, and Blood Institute
Grant: U54HL081007
National Cancer Institute
Grant: 1U54CA232568-01
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers
National Cancer Institute
Grant: P01 CA168585
National Cancer Institute
Grant: P01CA094237
National Cancer Institute
Grant: P01CA190174-05
National Cancer Institute
Grant: P30 CA008748
National Cancer Institute
Grant: P30CA125123
National Cancer Institute
Grant: P50CA126752
National Cancer Institute
Grant: R01 CA235667
National Cancer Institute
Grant: R01 CA236615-01
National Cancer Institute
Grant: R35 CA197633
National Institute of Allergy and Infectious Diseases
Grant: U01 AI087628
National Institutes of Health
Grant: 3P30CA125123-09S3
Baylor College of Medicine Cancer Center
National Institutes of Health
Grant: 5R01CA235667-02
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
National Institutes of Health
Grant: 3P01CA190174-04S1
Immunologic Approaches to Ovarian Cancer
National Institutes of Health
Grant: 5U54HL081007-03
Improving the safety and efficacy of cell therapies
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institutes of Health
Grant: 5P50CA126752-14
SPORE in Lymphoma
National Institutes of Health
Grant: 2R35CA197633-08
Next Generation Cancer Immunotherapies to Defeat Melanoma
National Institutes of Health
Grant: 5K01DK076973-05
Development and Safety Evaluation of Chemo-Protective Gene Therapy Vectors
National Institutes of Health
Grant: 5R01CA236615-02
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
National Institutes of Health
Grant: 1P01CA168585-01A1
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMAS
National Institutes of Health
Grant: 5R01CA114218-03
Hematopoietic Chemoprotection in Glioblastoma Patients
National Institutes of Health
Grant: 5U01AI087628-05
Gene Therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector
National Institutes of Health
Grant: 5P01CA094237-10
CELL PROCESSING
NHLBI NIH HHS
Grant: 75N92019D00018
Intramural NIH HHS
Grant: ZIA BC011823
NIDDK NIH HHS
Grant: K01 DK076973
NCI NIH HHS
Grant: R01 CA236615
NCI NIH HHS
Grant: U54 CA232568
NCI NIH HHS
Grant: P01 CA190174
NHLBI NIH HHS
Grant: P40 HL116242
NCI NIH HHS
Grant: R01 CA114218
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals